MedCon 2024, co-sponsored by the FDA

The premier medical device conference driving the speed of innovation.

Presented by AFDO / RAPS

Since 2009, MedCon has united regulators and healthcare products industry experts for unparalleled exchanges.

MedCon 2024 is hosted by AFDO/RAPS Healthcare Products Collaborative and co-sponsored by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services. The event will convene April 24-26 in Columbus for three days of purpose-driven discussions that harmonize different perspectives to inspire collaboration, lead innovation, and make a difference in patient care.

MedCon 2023 by the #s

300

attendees

65

Expert speakers

26

Topic sessions

30

FDA Speakers

4

Tracks

42

FDA PARTICIPANTS

14

Countries

5

continents

MedCon 2023 was full of topics and ideas relevant to our company and products. I came away with several actions to begin sharing within my company. I was able to speak with FDA attendees one-on-one to ask questions pertinent to our business.”

Ann Gill Photo

Ann Gill

Quality Engineer – Regulatory, Norwood Medical

An experience like no other!

MedCon 2024 is hosted by the AFDO/RAPS Healthcare Products Collaborative and sparks open, candid conversations between global regulators and industry experts to address challenges and improve patient care.

Join us April 24-26 in Columbus to experience:

An intensive full-day preconference workshop* and our two-and-a-half-day conference

Paradigm-shifting dialogue leading to immediately transformative – and practical – solutions

Proactive and predictive methods that will protect your products, businesses, and patients

Cross-functional insights that foster critical alignment and collaboration

*Separate registration is required for the workshop.

Why attend MedCon 2024?

2024 MedCon Program Lineup

Engage and contribute in plenaries aimed at breaking barriers and solving problems, along with in-depth breakouts and the Solutions Exchange! Sessions include: 

Best Practices for Engaging Patients and Using the Patient Perspective Over the Device Lifecycle

FDA’s PCCP Draft Guidance Deep Dive

International Influences on a Lifecycle Risk Management System

Regulators: Global Harmonization and Convergence Initiatives

News and Best Practices for Signals Involving Reports of Correction and Removal (806) and Adverse Events (MDRs)

Utilizing Effective Cybersecurity Risk Management as an Element of a Complete Risk Management Program

EU MDR and IVDR State of Play

Incorporating PMS Risk Assessment / HHEs Into Quality and Regulatory Systems

The Current State of Biocompatibility: Experience and Expectations

Medical Device Sterilization Sustainability: EPA’s New Rule, FDA Initiatives, and Industry’s Challenges

What You Need to Know About FDA’s Transition to Incorporate ISO 13485 by Reference Into 21 CFR 820 (QMSR)

“I can’t think of any other event where you can talk face-to-face with FDA and ask them specific questions about different laws and areas they regulate. Definitely one of the best reasons to attend MedCon!”

Ashleigh Rickey Photo

Ashleigh Rickey

Director of Quality Assurance, Hardy Diagnostics

2024 Speaker Highlights

Daniel Canos

FDA

Sean Boyd

FDA

Gina Brackett

FDA

Jacob Dyer

FDA

Sonja Fulmer

FDA

Jennifer Goode

FDA

Clarence Murray III

FDA

Josh Nipper

FDA

Jessica Paulsen

FDA

Mike Ryan

FDA

Jeff Shuren

FDA

Keisha Thomas

FDA

RAPS RAC Certification

Attend MedCon 2024 and earn 12.0 RAC recertification credits. 

2024 Sponsors

Because of the generosity of our sponsors, we can continue our work to improve the healthcare products industry.

Abbott - Sponsor

Diamond Sponsor

Zimmer Biomet - Sponsor

Platinum Sponsor

Steris - Sponsor

Platinum Sponsor

Eli Lilly, sponsor

Gold Sponsor

Johnson Johnson - sponsor

Gold Sponsor

Patrick Flynn Photo

Learn more about supporting MedCon 2024 through sponsorship by contacting Patrick Flynn at +1-301-770-2920, ext. 246, or pflynn@raps.org.

This conference is co-sponsored by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services. The contents are those of the presenters and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. government.